Combination treatment for recurrent nasopharyngeal cancer that cannot be removed by surgery
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests a new combination for people whose nasopharyngeal cancer has returned in the same area and cannot be removed by surgery. The treatment combines a targeted drug (becotatug vedotin), an immunotherapy (PD-1 antibody), and radiation to try to shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and generally able to care for yourself (ECOG 0 or 1).
- Your cancer has come back in the nose/throat area after initial radiation, but it is not removable with surgery.
- At least 12 months have passed since your first radiation treatment.
- You have at least one measurable tumor that can be seen on scans.
- You are not pregnant and agree to use contraception during the trial and for 6 months after the last dose.
- Your blood counts, liver, kidney, and clotting functions are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—an investigational antibody that targets cancer cells (MRG003) and a chemotherapy pill (capecitabine)—along with an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back but hasn't spread. The goal is to see if this approach can help control the cancer.
This trial tests a combination of three drugs (chidamide, toripalimab, and anlotinib) for people with nasopharyngeal cancer that has spread or come back. The goal is to see if this combination can help control the cancer when other treatments have not worked.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This study compares two combinations of drugs (tislelizumab plus either GX or GP) to see which works better for people with nasopharyngeal cancer that has returned or spread and has not been treated with systemic therapy before.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial studies a drug called MRG003 combined with another therapy that boosts the immune system to fight cancer. It aims to see if this combination can shrink tumors or slow the growth of nasopharyngeal cancer that has returned or spread.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.